| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hiroyuki Konya, Masayuki Miuchi, Kahori Satani, Satoshi Matsutani, Yuzo Yano, Taku Tsunoda, Takashi Ikawa, Toshihiro Matsuo, Fumihiro Ochi, Yoshiki Kusunoki, Masaru Tokuda, Tomoyuki Katsuno, Tomoya Hamaguchi, Jun-ichiro Miyagawa and Mitsuyoshi Namba |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hiroyuki Konya, MD, PhD, Department of Internal Medicine, Ashiya Municipal Hospital, 39-1, Asahigaoka-cho, Ashiya, Hyogo 659-8502,
Japan. h-dyer@mvi.biglobe.ne.jp |
| Key Words |
Asymmetric dimethylarginine; Biomarker; Diabetes mellitus; Cardiovascular complications; Incretin |
| Core Tip |
Asymmetric dimethylarginine (ADMA) is an emerging independent biomarker for prospective cardiovascular (CV) complications. In our study, the results show that the cases with a high level of ADMA could have diabetes mellitus CV (DMCV) complications in the future within five years. Furthermore, not only ADMA but also urinary albumin was associated with DMCV complications in the multiple regression analyses. The clinical acceptation of this parameter will rely on the availability of therapies to immediately reduce ADMA such as incretin-based drugs, which could support the part of ADMA as an etiologic risk factor. |
| Publish Date |
2015-05-21 14:15 |
| Citation |
Konya H, Miuchi M, Satani K, Matsutani S, Yano Y, Tsunoda T, Ikawa T, Matsuo T, Ochi F, Kusunoki Y, Tokuda M, Katsuno T, Hamaguchi T, Miyagawa J, Namba M. Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus. World J Exp Med 2015; 5(2): 110-119 |
| URL |
http://www.wjgnet.com/2220-315X/full/v5/i2/110.htm |
| DOI |
http://dx.doi.org/10.5493/wjem.v5.i2.110 |
